Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215

[PR Newswire] – Amgen (NASDAQ:AMGN) and Allergan plc. (AGN) today announced a Phase 3 study of biosimilar candidate ABP 215 met its primary and secondary endpoints. The study evaluated the efficacy and safety . . . → Read More: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215 Similar Articles: Company Update: Allergan Inc (NYSE:AGN) – Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215 Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.